Condition: High-Risk Non-Muscle-Invasive Bladder Cancer · Sponsor: CG Oncology, Inc.
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
This description comes directly from the study's public registry record.
Rebecca Tregunna, MD · 949 409-3700 · Rebecca.Tregunna@cgoncology.com
Pat Keegan, MD · 949 409-3700 · pat.keegan@cgoncology.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Arizona | Phoenix, Arizona, United States | Recruiting |
| Arizona Urology Specialty | Tucson, Arizona, United States | Withdrawn |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Arkansas Urology | Little Rock, Arkansas, United States | Recruiting |
| Michael G Oefelein, MD Clinical Trials | Bakersfield, California, United States | Recruiting |
| Genesis Research (Greater Los Angeles) | Los Alamitos, California, United States | Recruiting |
| Advanced Urology | Los Angeles, California, United States | Withdrawn |
| Urology Center of Southern California | Murrieta, California, United States | Recruiting |
| University of California, Irvine | Orange, California, United States | Recruiting |
| Om research | San Diego, California, United States | Recruiting |
| University of Southern California | San Diego, California, United States | Recruiting |
| Genesis Research (Greater Los Angeles) | Torrance, California, United States | Recruiting |
+ 53 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06567743